Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
about
Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series studyA Review of Pharmacological Management of Attention-Deficit/Hyperactivity DisorderAre there any potentially dangerous pharmacological effects of combining ADHD medication with alcohol and drugs of abuse? A systematic review of the literatureMethylphenidate use in children with attention deficit hyperactivity disorderMethylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trialsProfile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorderFrom Clinical Application to Cognitive Enhancement: The Example of MethylphenidateAttention-Deficit Hyperactivity Disorder and Long-QT Syndrome: Risky BusinessLong-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder.Does Methylphenidate Reduce Testosterone Levels in Humans? A Prospective Study in Children with Attention-Deficit/Hyperactivity Disorder.Hypertension in the Pediatric Kidney Transplant RecipientA systematic review of the safety of lisdexamfetamine dimesylate.ADHD and adolescent athletes.Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study.Legg-Calvé-Perthes disease and the risk of ADHD, depression, and mortalityExpanding medication options for pediatric ADHD.Liver Transplant in a Patient under Methylphenidate Therapy: A Case Report and Review of the LiteratureGuanfacine Extended Release: A New Pharmacological Treatment Option in Europe.Genetic screening in sudden cardiac death in the young can save future livesHeart Rate Variability in Children with Attention-Deficit/Hyperactivity Disorder: A Pilot StudyAttention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes.Nutrition, immunological mechanisms and dietary immunomodulation in ADHD.Safety of medicines used for ADHD in children: a review of published prospective clinical trials.Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.Acute and Long-Term Cardiovascular Effects of Stimulant, Guanfacine, and Combination Therapy for Attention-Deficit/Hyperactivity Disorder.The effect of atomoxetine, a selective norepinephrine reuptake inhibitor, on respiratory arrest and cardiorespiratory function in the DBA/1 mouse model of SUDEP.Atomoxetine, a norepinephrine reuptake inhibitor, reduces seizure-induced respiratory arrest.An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder.Gut microbiota and attention deficit hyperactivity disorder: new perspectives for a challenging condition.Is Mania the Hypertension of the Mood? Discussion of A Hypothesis.Adult ADHD: Questioning Diagnosis and Treatment in a Patient with Multiple Psychiatric Comorbidities.Evaluation of acute cardiovascular effects of immediate-release methylphenidate in children and adolescents with attention-deficit hyperactivity disorderThe cardiovascular safety of methylphenidateSafety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials.Comprehensive review of cardiovascular toxicity of drugs and related agents.Evaluation of dosage, safety and effects of methylphenidate on post-traumatic brain injury symptoms with a focus on mental fatigue and pain.Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling?Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder.Life-threatening QT prolongation in a boy with attention-deficit/hyperactivity disorder on atomoxetine.
P2860
Q24658644-33BC7B90-D09A-4AA9-8D80-377B81CFEBDCQ26741896-0FE8A3F7-BC94-4B64-9641-EBC877D33F22Q26777710-102E8A20-6B09-4665-BAF6-61E3134AE0A2Q26824793-12A8CFEA-CC12-4E78-AE6E-A9903A035630Q27007856-811C5CB5-5730-4ADB-9E92-554EF2AF7863Q27692647-593EDD46-1E6C-4078-9472-8BC7624841F4Q28073785-E33D503A-AC4F-45FA-99D0-42497705826EQ33165891-21F15C54-48EA-41FC-9B51-CCF865A1BE04Q33165982-C22264D3-B90D-4214-9F8A-BE68C29706F6Q33614158-71E3F94E-6F46-4109-B8DD-685C98E76658Q33619380-B9097B24-543C-43D8-AA47-C37323F68E7CQ33755396-CE83A61B-C734-4817-85E1-B2D8ED87D069Q33764804-F884E76C-9B5C-4C45-8DFD-6A93999C2516Q34063584-2D710F3A-C27D-4307-B585-BF6163F33392Q34185365-90168004-9388-49E6-8E06-186010AAAA6DQ34976160-B09BFF8C-F029-4C3D-992F-C52F42D3CABCQ35061587-41214057-CEAA-49A8-A721-5B1CEFFE7D5AQ36446854-93F08275-342A-4C04-A44F-CF602F54A96BQ36460505-68E8D9F9-4067-4141-A88B-E45C6CFC4F04Q37251112-16015426-32A3-47F8-B5E9-4123532A382BQ37722786-77F9E2D8-4AC1-4DF9-9024-6B847FCAC07BQ38184947-A7AE4B27-7E87-4933-A21A-5A147C6E2245Q38205749-421F1FD8-B9CB-4953-BBE0-1BD5D9336324Q38242438-287CBCCA-1CDE-483F-838B-93AC9BD85FBAQ38374695-81768156-6172-4B4C-AC65-A20C57E20C81Q38389306-6A19EF85-792D-4061-A2B1-88F0C68EDF61Q38606842-FCCFE3F0-5518-4BC5-8C5C-5F1BCA3764E9Q38729759-E89DCFDD-55D9-430A-A337-71D5843C1216Q39170905-4E2F375C-29BC-4F7F-9DAA-A9020BBE22D5Q39177006-CC749F7B-6D5D-43E2-AFBF-BF3CE3C12A19Q39305705-096BC3DD-AEC9-4DB7-8CCC-7CCBB70BAC69Q39427310-7F7BD098-9C22-4AE9-BBAD-F3329C1E86DBQ40654140-4CC3B6FA-9E82-44FE-8DD3-26346D05BD7CQ42748697-0F6B7A11-A62A-4470-AE87-95F67D7E6AE1Q44649953-5B443564-94F3-44B5-A896-5A1340888276Q47556269-D4C8308F-B592-4D3A-90D3-79E9CCE3F137Q47814827-98FE0A6D-9C99-4976-BA7D-72A8FF1F2585Q50155852-34196ACC-20B8-4EEE-AEC9-839FA5841ED3Q50576718-77F881E2-EB62-440C-A4BA-D284F2FEDC61Q52303496-1265FA88-A4D3-48B9-97B4-42F1572D0447
P2860
Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Risk of serious cardiovascular ...... eficit hyperactivity disorder.
@en
type
label
Risk of serious cardiovascular ...... eficit hyperactivity disorder.
@en
prefLabel
Risk of serious cardiovascular ...... eficit hyperactivity disorder.
@en
P2093
P2860
P1433
P1476
Risk of serious cardiovascular ...... deficit hyperactivity disorder
@en
P2093
Carlos Knecht
María I Martinez
Nestor Szerman
P2860
P2888
P356
10.1007/S40263-012-0019-9
P577
2013-01-01T00:00:00Z